Osteoporosis International

, Volume 24, Issue 1, pp 1–6 | Cite as

The effect of treatments for osteoporosis on mortality

  • A. GreyEmail author
  • M. J. Bolland


The incidence of osteoporotic fractures increases exponentially in later life, in parallel with the progression of frailty and the risk of dying. Several pharmacologic therapies are now available that reduce the risk of fragility fractures. Data from observational studies report that osteoporotic fractures are associated with an increased risk of dying, particularly in the first few years after an event, and that, in osteoporotic populations, bisphosphonate therapy is associated with a reduced risk of death. Data emerging from randomised controlled trials suggest that drugs which significantly reduce fracture risk might also prolong survival in osteoporotic populations. Further research into the nature, magnitude and mechanisms of the effects of osteoporosis treatments on mortality is required, but in the interim, clinicians and their patients should consider the available data in their deliberations about the use of these medications.


Fracture Mortality Osteoporosis Treatment 



Grant support from the Health Research Council of New Zealand. Dr Bolland is the recipient of a Hercus Fellowship from the Health Research Council of New Zealand.

Conflicts of interest



  1. 1.
    Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767PubMedCrossRefGoogle Scholar
  2. 2.
    Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20:1633–1650PubMedCrossRefGoogle Scholar
  3. 3.
    Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRefGoogle Scholar
  4. 4.
    Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar
  5. 5.
    Browner WS, Seeley DG, Cummings SR, Vogt TM (1991) Non-trauma mortality in elderly women with low bone mineral density. Lancet 338:355–358PubMedCrossRefGoogle Scholar
  6. 6.
    Browner WS, Pressman AR, Nevitt MC, Cummings SR (1996) Mortality following fractures in older women: the Study of Osteoporotic Fractures. Arch Intern Med 156:1521–1525PubMedCrossRefGoogle Scholar
  7. 7.
    Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882PubMedCrossRefGoogle Scholar
  8. 8.
    Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 209:513–521CrossRefGoogle Scholar
  9. 9.
    Empana J-P, Dargent-Molina P, Breart G (2004) Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 52:685–690PubMedCrossRefGoogle Scholar
  10. 10.
    Ioannidis G, Papaioannou A, Hopman WM et al (2009) Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. Can Med Assoc J 181:265–271CrossRefGoogle Scholar
  11. 11.
    Ismail AA, O'Neill TW, Cooper C et al (1998) Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 8:291–297PubMedCrossRefGoogle Scholar
  12. 12.
    Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, Laet CD, Jönsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38PubMedCrossRefGoogle Scholar
  13. 13.
    Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561PubMedCrossRefGoogle Scholar
  14. 14.
    Ziade N, Jougla E, Coste J (2010) Population-level impact of osteoporotic fractures on mortality and trends over time: a nationwide analysis of vital statistics for France, 1968–2004. Am J Epidemiol 172:942–951PubMedCrossRefGoogle Scholar
  15. 15.
    LeBlanc ES, Hillier TA, Pedula KL et al (2011) Hip fracture and increased short-term but not long-term mortality in healthy older women. Arch Intern Med 171:1831–1837PubMedCrossRefGoogle Scholar
  16. 16.
    Kanis J, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473PubMedCrossRefGoogle Scholar
  17. 17.
    Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA (2011) Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 96:1006–1014PubMedCrossRefGoogle Scholar
  18. 18.
    Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, Majumdar SR (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22:983–991PubMedCrossRefGoogle Scholar
  19. 19.
    Sambrook PN, Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, Seibel MJ (2011) Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 22:2551–2556PubMedCrossRefGoogle Scholar
  20. 20.
    Bondo L, Eiken P, Abrahamsen B (2012) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study. Osteoporos Int. doi: 10.1007/s00198-012-2024-8
  21. 21.
    Cree MW, Juby AG, Carriere KC (2003) Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int 14:722PubMedCrossRefGoogle Scholar
  22. 22.
    Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174–1181PubMedCrossRefGoogle Scholar
  23. 23.
    Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97PubMedCrossRefGoogle Scholar
  24. 24.
    Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRefGoogle Scholar
  25. 25.
    Ural AU, Avcu F, Ozturk K (2008) Bisphosphonates may retrieve endothelial function in vascular diseases similar to statins’ effects. Eur J Hematol 81:77–78CrossRefGoogle Scholar
  26. 26.
    Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F, Poccia F, Gessani S (2005) Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 174:252–260PubMedGoogle Scholar
  27. 27.
    Maksymowych W (2002) Bisphosphonates: anti-inflammatory properties. Curr Med Chem 1:15–28Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2012

Authors and Affiliations

  1. 1.Department of MedicineUniversity of AucklandAucklandNew Zealand
  2. 2.AucklandNew Zealand

Personalised recommendations